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Abstract
Phosphatase of regenerating liver 3 (PRL-3) is known to be overexpressed in many tumors, and its transcript level is high in
the vasculature and endothelial cells of malignant tumor tissue. However, the mechanism(s) underlying its enhanced
expression and its function in endothelial cells remain unknown. Here, we report that vascular endothelial growth factor
(VEGF) can induce PRL-3 transcription in human umbilical vein endothelial cells (HUVEC). An analysis of its 59UTR revealed
that PRL-3 transcription is initiated from two distinct sites, which results in the formation of the two transcripts, PRL-3-iso1
and PRL-3-iso2, but only the latter is up-regulated in HUVEC by VEGF. The PRL-3-iso2 promoter region includes two
functional MEF2 (myocyte enhancer factor2) binding sites. The over-expression of the constitutively active form of MEF2C
promotes the abundance of the PRL-3-iso2 transcript in a number of human cell lines. The siRNA-induced knockdown of
MEF2C abolished the stimulative effect of VEGF on PRL-3 transcript in HUVEC, indicating that the VEGF-induced promotion
of PRL-3 expression requires the presence of MEF2C. Finally, blocking PRL-3 activity or expression suppresses tube formation
by HUVEC. We suggest that PRL-3 functions downstream of the VEGF/MEF2C pathway in endothelial cells and may play an
important role in tumor angiogenesis.
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Introduction
PRL-3 is a member of the phosphatase of regenerating liver
(PRL) family which represents a novel family of small (,22 kDa)
highly homologous protein tyrosine phosphatases (PTPs) [1]. Since
the presence of PRL-3 was first linked with colon cancer metastasis
in 2001 [2], evidence has accumulated that this protein is
associated with various oncogenic and metastatic processes [3].
PRL-3 is abundant in many cancer cell lines and metastatic
lesions, including gastric cancer [4], malignant melanoma cancer
[5], ovarian cancer [6], breast cancer [7], colonic cancer [8] and
esophageal squamous cell carcinoma [9]. For this reason, it is now
commonly referred to as a metastasis-associated phosphatase
[10,11,12], and its importance in cancer cell invasion and
migration has been widely demonstrated [13,14,15].
Within a developing tumor, oxygen and nutrition are supplied
via angiogenesis. VEGF is released into the extracelluar matrix by
cancer cells to stimulate the migration of endothelial cells towards
the source of the VEGF signal, where they proceed to form
immature vessels via vasculogenesis or angiogenic sprouting
[16,17]. MEF2C, a member of the myocyte enhancer factor 2
(MEF2) family of transcription factors originally identified as
activators of muscle differentiation [18,19], appears to play a
particularly important role in angiogenesis during vascular
development. The deletion of MEF2C in mice results in
embryonic lethality associated with significant cardiovascular
defects, and the phenotype of MEF2C deficient mice is similar
to that of mice lacking VEGF [20,21,22]. VEGF has also been
reported to induce the expression of MEF2C and to stimulate
MEF2-dependent activity in endothelial cells [20,23].
PRL-3 expressing cancer cells are able to recruit endothelial cells
for the initiation of tumor angiogenesis [24]. It has also been
suggested that PRL-3 induces microvascular and lymphatic
formation in lung cancer tissues associated with elevated VEGF
expression [25]. PRL-3 transcript is abundant both in malignant
tumorandmetastaticlesions,butalso invasculature andendothelial
cells within a malignant tumor mass [2,7,10,26,27,28,29]. PRL-3
therefore appears to play a role in tumor-associated endothelial
cells, but neither the control of PRL-3 mRNA expression in tumor
endothelial cells nor the significance of PRL-3 over-expression for
the function of these cells is well understood. In normal mouse and
human tissues, PRL-3 transcript is found predominantly in skeletal
muscle and heart [1,24,30], but the identity of the controlling
transcription factors is not well defined. Although Basak et al. [31]
reported that mouse prl-3 gene was a direct target of P53 during
DNA damage-induced cell cycle arrest, considering its expression
pattern in normal tissues, it is quite possible that the transcription of
human PRL-3 is under the control of cardiac- or muscle-specific
transcription factors.
Here, we demonstrate that VEGF can induce PRL-3 transcrip-
tion in HUVEC through the transcription factor MEF2C, and
that both PRL-3 inhibitor and siRNA-induced knockdown can be
used to suppress the tube formation by HUVEC. We suggest on
this basis that PRL-3 is a downstream component of the VEGF/
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e27165MEF2C pathway in endothelial cells, and that it may play an
important role in tumor angiogenesis.
Materials and Methods
Cell culture
HEK293T, Hela, A375, A549, MCF7, SW480 cells, all
obtained from the Institute of Biochemistry and Cell Biology
(Shanghai, China), were cultured in DMEM supplemented with
penicillin (100 U/ml), streptomycin (100 mg/ml) and 10% v/v
FBS (Life Technologies Inc., Grand Island, NY). HUVEC
(provided by Decai Yu in Gulou Hospital, Nanjing, China) were
cultured in EGM2-MV medium (Lonza) and used at passages 4 to
12. Cells were grown in 5% v/v CO2 at 37uC, and the medium
was replaced every 2–3 days.
Localization of the PRL-3 transcription start site
The PRL-3 transcription start site was located in HUVEC,
293T and Jurkat cells using a GeneRacer kit (Invitrogen),
according to the manufacturer’s instructions. The initial 59RACE
PCR used cDNAs as templates, primed with the 59 primer
supplied with the kit and PRL-3 primer GSP (59-CCAAAG-
TAAAGCGGGCAACTCCAA-39). The amplification regime
comprised an initial denaturation step (94uC/5min), followed by
30 cycles of 94uC/30s, 60uC/30s, 72uC/45s, ending with an
elongation step of 72uC/5min. The second PCR used the primary
PCR products as templates, primed with the 59 nested primer
supplied with the kit and the PRL-3 primer nested GSP (59-
GCAACTCCAAACTCCCGTCTCTC-39). The amplification
regime was identical to the above, except that the annealing
temperature was set to 65uC rather than 60uC. The amplicon was
gel-purified using a gel extraction kit (OMEGA, USA) and cloned
into the TOPO-TA Cloning vector (Invitrogen) for subsequent
sequencing.
Construction of luciferase reporter plasmids
A series of PRL-3 promoter plasmids were constructed by
cloning the PRL-3-iso2 promoter region into the pGL3 basic vector
(Promega, Madison, WI, USA), and their names are based on the
position of the inserted sequence’s 59 most nucleotide relative to
the transcription start site. Briefly, a DNA fragment containing the
PRL-3 promoter region was amplified from HUVEC DNA and
cloned into the pGL3 basic vector using primers in Table S1.
Recombination PCR was performed as described previously [32]
to introduce mutations into the MEF2 binding sites based on luc-
158, using the primers listed in Table S2. Briefly, the products
amplified by primer pairs P1 and P2 (or P3 and P4) were ligated to
one another using a two-step PCR procedure. The ligated
sequence was then inserted into the pGL3 vector.
Plasmid constructs
The MEF2C coding region was amplified from total RNA
isolated from human skeletal muscle using the following primer
pair: 59-GGAGCTAGCGGACTATGGGGAGAAAAA-39 and
59- ACAGAGCTCATCATGTTGCCCATCCTT-39. The result-
ing amplicon was inserted into the PcDNA3.1 (2) NheI/XhoI
cloning site. MEF2-DBD-VP16-ER and MEF2-DDBD-VP16-ER
(the latter lacking the core residues responsible for MEF2 DNA
binding) are kindly provided by Dr. Michael Greenberg [33]. The
ER sequence ensures that MEF2-DBD-VP16-ER remains in the
cytoplasm of the transfected cells and rapidly translocates into the
nucleus to activate MEF2-dependent transcription upon 4-
hydroxyl-tamofxifen (4OHT) stimulation. MEF2-DBD-VP16
and MEF2-DDBD-VP16 were subcloned from MEF2-DBD-
VP16-ER and MEF2-DDBD-VP16-ER into the PcDNA3.1 (2)
vector, while MEF2-DBD-NLS and MEF2-DDBD-NLS repre-
sented fusions of the nuclear localization signal (NLS) domain of
MEF2C with either the MEF2-DBD or MEF2-DDBD domain of,
respectively, MEF2-DBD-VP16-ER and MEF2-DDBD-VP16-
ER.
Transfection and luciferase assay
HEK293T cells were cultured in 24-well plates and transiently
transfected with the PRL-3 promoter reporters using Lipofecta-
mine 2000 (Invitrogen). The transfection process involved the
introduction of 0.5 mg luciferase reporter plasmid and 0.1 mgo fb-
gal vector; MEF2 plasmids were included where necessary. After
48 h, luciferase activity was detected using the Luciferase Assay
System (Promega) and b-Galactosidase using the b-Galactosidase
Enzyme Assay System (Promega), both according to the
manufacturer’s instructions. Each transfection was carried out in
triplicate. For the knockdown assay, either 200 pM of a non-
targeting siRNA or MEF2C-specific siRNA (Stealth
TM RNA,
Invitrogen), or various concentrations of PRL-3-specific siRNA,
was transfected into cells using Lipofectamine 2000. The
sequences of MEF2C siRNAs (#1, #2, #3) and PRL-3 siRNA
are listed in Table S5.
Electrophoretic mobility shift assay (EMSA)
Nuclear extracts were prepared from HEK293T cells transfect-
ed with the MEF2C plasmid using NE-PER nuclear and
cytoplasmic extraction reagents (Pierce, Rockford, IL, USA)
according to the manufacturer’s instructions. Synthetic oligonu-
cleotides 59-labeled with biotin (Invitrogen) were annealed to
generate double-stranded oligonucleotides as probes (Table S3).
EMSA was performed according to the instructions provided with
the LightShift Chemiluminescent EMSA kit (Pierce). Briefly, 1 ml
of nuclear extract was incubated at room temperature for 20 min
in the presence of 1 ml binding buffer, 20 fmol of biotinylated
probe, 0.5 ml glycine, 0.5 ml MgCl2, 0.5 ml NP40 and 1 ml
Poly(dI.dC) in a reaction volume of 10 ml. Then 2.5 mlo f
56loading buffer was added and the sample electrophoresed
through a 4% non-denaturing polyacrylamide gel in 0.56TBE at
4uC. For competition experiments, unlabelled wild-type oligonu-
cleotide was added in a 1006molar excess prior to the addition of
the biotinylated probe. To identify the transcription factor present
in the DNA protein complex using a supershift assay, the nuclear
extracts were incubated in the binding buffer for 60 min at 4uCi n
the presence of MEF2C or IgG antibody (Santa Cruz Biotech-
nology, Santa Cruz, CA, USA) prior to the addition of the
biotinylated probe.
Chromatin Immunoprecipation assay
The ChIP assay was performed as described previously [34].
Either anti-MEF2C or anti-IgG antibodies were used for
immunoprecipation. The primers used to amplify the region
containing MEF2 binding sites were 59-CGGCGGGAGGAAG-
GAGGGGT-39 and 59-GCTGCCGCCACCGCCGCCTG-39.
RT-PCR and Real-time PCR
A1mg aliquot of total RNA extracted from cells with the Trizol
reagent (Invitrogen, Carlsbad, CA) was converted to cDNA using
M-MLV reverse transcriptase (Toyobo, Osaka, Japan) according
to the manufacturer’s instructions. RT-PCR was performed using
primers listed in Table S4. Real-time PCR was performed on an
ABI Prism 7300 system device (Applied Biosystems, Foster City,
CA), using SYBR Green I dye (Biotium, Inc.).
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The Western blotting procedure followed standard protocols.
HEK293T cells, after being transfected with plasmids or siRNA as
indicated for 48 hours, were collected and lysed in 50 mM Tris
(pH 8.0), 150 mM NaCl, 1% NP-40, 0.1% SDS, 5 mM EDTA,
0.1 mM PMSF, 0.15 U/mL aprotinin and 1 mg/mL pepstatin.
Anti-PRL-3 (kindly provided by Zeng Qi, Institute of Molecular
and Cell Biology, Singapore, Singapore), anti-MEF2C and anti-
GAPDH (Santa Cruz Biotechnology) antibodies were used for
detection.
HUVEC tube formation assay
A tube formation assay was performed as described previously
[35]. Briefly, 2610
4 HUVEC were seeded in triplicate in a 96-well
plate pre-coated with Matrigel (BD) in EGM2 medium in either
the presence or absence of various concentrations of PRL-3
inhibitor P0108 (Sigma) at 37uC in a 5% v/v CO2 humidified
atmosphere. For the PRL-3 knockdown assay, cells were
transfected with various concentrations of PRL-3 specific siRNA
for 48 h, and then seeded in triplicate in a 96-well plate. After
24 h, cell images were captured and analyzed.
Figure 1. VEGF activates PRL-3 transcription in HUVEC. (A) HUVEC were stimulated by the addition of various concentrations of VEGF for 24 h.
(B) The time course of PRL-3 transcription in response to 100 ng/ml VEGF. RPL-3 mRNA level was evaluated by real-time PCR. Control is the untreated
cells. (C) Schematic of the PRL-3 gene indicating the transcription initiation sites and its exon/intron structure. VEGF selectively increases the
abundance of the PRL-3-iso2 (E) but not the PRL-3-iso1 (D) transcript in HUVEC treated with 100 ng/ml VEGF for 24 h. The expression (real-time PCR)
data reflect the mean 6 SD from three independent experiments. * significantly different from the control at P,0.05.
doi:10.1371/journal.pone.0027165.g001
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Data were expressed as mean 6 SD. The student’s t-test was
used to attach statistical significance to differences between means,
applying a P,0.05 or 0.01 criterion.
Results
VEGF activates PRL-3 transcription in HUVEC
Because PRL-3 is highly expressed in the vasculature and
endothelial cells of malignant tumor mass and its protein can only
be detected in developing blood vessels, it is interesting to explore
whether VEGF, a growth factor proven to be important for blood
vessel formation, could induce PRL-3 expression in endothelial cells.
When HUVEC were exposed to either 50 ng/ml or 100 ng/ml
VEGF for 24 h, the abundance of PRL-3 transcript rose
significantly (Fig. 1A). The level plateaued after 24 h, remaining
high for the following 24 h (Fig. 1B). The PRL-3 transcription start
site was obtained using the 59RACE method. After cloning its
59UTR (sequence given in Supplementary Sequence S1) the
alignment of the resulting sequence suggested two distinct
transcription start sites, one lying 30232 bp and the other
4313 bp upstream of the ATG codon. As a result, two distinct
PRL-3 transcripts were predicted (PRL-3-iso1 and PRL-3-iso2) which
differ with respect to their first exon and intron (Fig. 1C). Using
primers specific to each transcript, it could be shown that VEGF
selectively induced the transcription of PRL-3-iso2, while it had no
effect on the level of PRL-3-iso1 transcription (Fig. 1D and E).
MEF2 binding sites are critical for the promoter activity of
PRL-3
Next, the PRL-3-Iso2 promoter region between 2131 bp
upstream and either 76 bp or 603 bp downstream of the
transcription start site was cloned into a luciferase reporter
construct. The two constructs induced a similar high level of
luciferase activity in 293T cells (Fig. S1), indicating that the region
upstream of +76 determined all the transcriptional activity. A
series of truncated PRL-3 promoter region constructs were
therefore assembled; the level of luciferase activity decreased to
almost zero as the 59 truncation point was moved from to 22131
to 21740, 21255, 2826 and 2158 and finally to 233 (Fig. 2A).
The sequence between 2158 and 233 was queried using www.
genomatix.de, revealing the presence of two MEF2 binding sites:
M1 lying between 2128 and 2119 (CTATATTTAG) and M2
from 249 to 240 (CTATAAATAG). As PRL-3 transcript is
abundant in heart and skeletal muscle where the presence of
MEF2 is known to be critical, it appears likely that the deletion of
the two MEF2 binding sites was responsible for the above
observed transcriptional activity. To verify this hypothesis, site-
directed mutations were introduced into the M1 and M2
sequences, and these did indeed result in a drastic decrease in
luciferase activity (Fig. 2B). Thus we concluded that the MEF2
binding sites are important for the transcriptional activity of the
PRL-3 promoter.
MEF2C binds to PRL-3 promoter in vitro and in vivo
EMSA was applied to establish whether the two MEF2 binding
sites were able to bind MEF2C. DNA-protein complexes were
detected when wild-type labeled MEF2-M2 probes were used
(Fig. 3A, lane 1) but not when using mutated probes (lane 3). The
complexes formed were competitively blocked in the presence of
excess unlabeled probes (lane 2). Adding a variable quantity
(0.008 mg, 0.04 mg, 0.2 mg) of anti-MEF2C antibody induced the
formation of a supershift band in a dose-dependent manner (lane
4–6), which was not inducible by the addition of an IgG antibody
Figure 2. MEF2 binding sites are critical for the promoter activity of PRL-3. (A) The region between 2158 and 233 is important for the
transcriptional activity of the PRL-3 promoter, as measured by luciferase activity. (B) The effect of site-directed mutations in the MEF2 binding sites, as
measured by luciferase activity. All luciferase activity were normalized to b-galactosidase activity and standardized to the normalized activity of pGL3-
Basic. Each column represents the mean 6 SD of three independent experiments. ** significantly different from the control at P,0.01.
doi:10.1371/journal.pone.0027165.g002
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just the MEF2C antibody (lane 8). MEF2C also bound successfully
to both MEF2-M1 and MEF2-M2 sites, although the binding
ability to the former site was less strong (Fig. S2). The same
interaction was investigated in vivo using the ChIP assay. As shown
in figure 3B, the anti-MEF2C antibody specifically immunopre-
cipitated the PRL-3 promoter in 293T cells while the IgG antibody
did not (Fig. 3B).
MEF2C promotes the transcriptional activity of the PRL-3
promoter
To determine whether PRL-3 expression can be regulated by
MEF2C, the constitutively active form of MEF2C (MEF2-DBD-
VP16-ER) and the dominant negative MEF2C (MEF2-DBD-
NLS), were introduced in conjunction with a luciferase assay. The
luciferase activity was greatly increased by the former in the
presence of 4OHT, while it was markedly reduced by the latter
(Fig. 4A). In several human cell lines, the former also increased the
abundance of the PRL-3-Iso2 transcript, but had no effect on the
abundance of the PRL-3-Iso1 transcript (Fig. 4B, S3). However,
there was no concomitant increase in the abundance of the protein
product (Fig. S4), indicating that the translation of PRL-3 is strictly
regulated.
MEF2C is required for VEGF- induced transcription of PRL-
3 in HUVEC
Since VEGF induces the expression of MEF2C, it was of
interest to explore the role of VEGF in determining PRL-3
transcription mediated by MEF2C. For this purpose, a siRNA
strategy was employed to knockdown the production of MEF2C in
HUVEC, and then to stimulate these cells with VEGF. Two
siRNA oligoes (#1 and #3) successfully reduced the transcription
of both constitutive and VEGF-induced MEF2C (Fig. 5B) and
PRL-3-Iso2 (Fig. 5C), but had no effect on that of PRL-3-Iso1
(Fig. 5D). We concluded that VEGF can indeed induce the
production of the PRL-3-Iso2 transcript in HUVEC through
transcription factor MEF2C.
Figure 3. MEF2C binds to the PRL-3 promoter both in vitro and
in vivo. (A) MEF2C binds in vitro to the MEF2 binding site M2 in the
promoter region of PRL-3-iso2. The EMSA used MEF2-M2 wild-type and
mutated probes and nuclear extracts from 293T cells transfected with
PcDNA3.1-MEF2C. (B) MEF2C binds to the PRL-3 promoter region in
vivo. The crosslinked DNA-protein complex extracted from 293T cells
was sonicated and immunopreciptated with either anti-IgG or anti-
MEF2C antibody, and then the DNA present in the immunoprecipitate
was extracted and used as a template for PCR. 1 ml of sonicated
chromatin was used as template for the input. The data are
representative of three independent experiments.
doi:10.1371/journal.pone.0027165.g003
Figure 4. Human PRL-3 transcription is regulated by MEF2C. (A) The effect of MEF2 plasmid on the luciferase activity of luc-158. Twenty-four
hours after transfection, 293T cells were stimulated with 4-OHT for another 24 h and harvested for luciferase assay. (B) The constitutively active form
of MEF2C up-regulated PRL-3-iso2 mRNA in several human cell lines. Cells were transfected with the indicated plasmids for 48 h and PRL-3 mRNA level
was evaluated by real-time PCR.
doi:10.1371/journal.pone.0027165.g004
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Finally, we tried to investigate the role of PRL-3 in an
endothelial cell function, tube formation. When the function of
PRL-3 was disrupted either by the presence of the specific
inhibitor P0108, or by the siRNA-induced knockdown of PRL-3
expression, tube formation by HUVEC was compromised (Fig. 6).
This behavior was consistent with the observation that over-
expression of PRL-3 in HUVEC promotes tube formation [28].
Discussion
PRL-3 is a metastasis-associated phosphatase whose ectopic
expression can markedly enhance cancer cell invasion and
migration. The gene is highly expressed in tumor associated
endothelial cells, including vasculature and endothelial cells in
colorectal cancer [26], glioma tumor tissue [29] and invasive
breast cancer [27]. It is implicated in the enhancement of the
migration capacity of endothelial cells, at least in vitro [7]. Here, we
have shown that VEGF can induce PRL-3 transcription in
HUVEC, mediated by the transcription factor MEF2C, which
suggests the existence of a novel VEGF/MEF2C/PRL-3 signaling
pathway in endothelial cells.
PRL-3 possesses two distinct transcription start sites (Fig. 1C),
which suggests that its transcription is controlled by two
independent promoters. The PRL-3 promoter region suggested
by the GeneBank entry (NM_032611) [36,37], in reality lies within
the gene’s first intron. As VEGF selectively induced the production
of the PRL-3-iso2 transcript, only the second promoter was
sensitive to VEGF stimulation (Fig. 1D, E). Possibly therefore, the
PRL-3-iso1 transcript represents the constitutive level of PRL-3
expression while the PRL-3-iso2 transcript is VEGF-inducible.
This could explain the high abundance of PRL-3 transcript in
tumor-associated endothelial cells, since tumor cells are able to
release VEGF into the extracellular matrix [16]. Experimentally, it
was possible to detect a substantial level of VEGF in the
supernatant after a 24 h culturing of the colon cancer cell lines
SW480 and SW620 (data not shown).
In normal mouse and human tissues, PRL-3 mRNA is found
predominantly in skeletal muscle and heart [1,24,30], which
implies that the gene is regulated by cardiac- or muscle-specific
transcription factors. Here, two functional MEF2 binding sites
have been located in its promoter region (Fig. 2B, Fig. 3).
Coincidently perhaps, the promoter region of Nur77, a gene
known also to be regulated by the MEF2 family [38,39], also
Figure 5. MEF2C is required for VEGF-induced production of the PRL-3-iso2 transcript in HUVEC. (A) The 293T cell line was co-transfected
with PcDNA3.1-MEF2C and siRNAs targeting either MEF2C or a control (NT) sequence. Twenty-four hours later, cells were collected and lysed, and
then protein levels of MEF2C and GAPDH were detected by Western blot analysis. (B, C, D) Knockdown of MEF2C suppresses the production of
endogenous and VEGF-induced MEF2C and the PRL-3-iso2 transcript, but has no effect on the abundance of the PRL-3-iso1 transcript. HUVEC were
transfected with #1 and #3 siRNAs specific for MEF2C or a non-targeting sequence (NT). Forty-eight hours after transfection, cells were treated with
100 ng/ml VEGF for another 24 h and then assessed for gene expression using real-time-PCR. The data reflect the mean 6 SD from three independent
experiments. * significantly different from the control at P,0.05.
doi:10.1371/journal.pone.0027165.g005
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conceivable that MEF2 plays a key role in PRL-3 transcription.
The constitutively active form of MEF2C increased PRL-3
transcription, and enhanced the abundance of both PRL-3-iso2
and Nur77 transcripts in several human cell lines (Fig. 4 and data
not shown). Although PRL-3 transcription was clearly enhanced by
the presence of MEF2C, there was no equivalent enhancement of
the protein level (Fig. S3). It has been reported recently that the
abundance of PRL-3 protein is not directly associated with the
level of its transcript, and that PCBP1 can suppress PRL-3
translation by binding to its 59UTR [36]. In addition, FKBP38 is
known to promote the degradation of endogenous PRL-3 protein
[41]. We assume that both the suppression of translation and the
promotion of degradation may be released in the micro-
environment conditions existing within a malignant tumor or
metastases site, thereby allowing the VEGF-induced PRL-3
transcripts to be readily translated.
Using a knockdown strategy, it was possible to show that
VEGF-induced PRL-3 transcription is mediated by MEF2C
(Fig. 5), implying the existence in endothelial cells of an as yet
undescribed VEGF/MEF2C/PRL-3 signaling pathway. PRL-3 is
known to induce microvascular and lymphatic formation in lung
cancer tissues, and this phenomenon has been associated with an
increased level of VEGF expression [25]. Either the addition of a
PRL-3 inhibitor, or the reduction in PRL-3 levels obtained by
siRNA knockdown, inhibited tube formation in in vitro cultured
HUVEC (Fig. 6). Together with the finding that PRL-3
contributes to angiogenesis in tumors [25], we suggest that cancer
cells containing an abundance of PRL-3 tend to more freely
release VEGF into the extracelluar matrix, which acts to stimulate
PRL-3 expression in endothelial cells via the VEGF/MEF2C
pathway, and helps to initiate tumor angiogenesis. Thus, PRL-3
may represent a rational drug target for cancer therapy, because in
attempting to neutralize PRL-3, not just the cancer cells
themselves, but also their associated endothelial cells are targeted.
In conclusion, we have shown that the transcription of human
PRL-3 is initiated from two distinct sites, resulting in the formation
of two novel PRL-3 transcripts. VEGF selectively induces the
Figure 6. The presence of PRL-3 is required for tube formation by HUVEC cultured on matrigel. (A) HUVEC were seeded into 6-well
plates precoated with matrigel in EGM2 medium in the presence of various concentrations of PRL-3 inhibitor (left panel). HUVEC were transfected
with various concentrations of human PRL-3 specific siRNA for 48 h, and then cells were harvested and seeded into 6-well plates precoated with
matrigel in EGM2 medium (right panel). (B) Representative images from three independent experiments.
doi:10.1371/journal.pone.0027165.g006
Figure 7. Hypothesized schematic diagram for VEGF/MEF2C/
PRL-3 signaling in endothelial cells. In malignant tumor tissues,
endothelial cells can be exposed to VEGF secreted from the cancer cells.
VEGF induces the expression and activity of MEF2C, which elevates PRL-
3 transcription in the endothelial cells. Then PRL-3 promotes tube
formation or angiogenesis in the endothelial cells within the tumor
tissue.
doi:10.1371/journal.pone.0027165.g007
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transcription factor MEF2C, suggesting an important role for
both MEF2C and PRL-3 in endothelial cells function, and in
particular in tumor angiogenesis (Fig. 7). We hope that these
findings will facilitate further investigation of the mechanisms
underlying the regulation of PRL-3 expression, and provide a
better understanding of the role of PRL-3.
Supporting Information
Figure S1 Regions upstream of the transcription start site
determine most of the transcriptional activity of the PRL-3
promoter. The promoter constructs (containing regions from
22131 to either +603 or +76 relative to the transcription start site)
were co-transfected with a b-gal plasmid into HEK293T cells.
Luciferase activity in the transfected cells was measured after 48 h.
Each column represents the mean 6 SD of three independent
experiments. ** significantly different from the control at P,0.01.
(TIF)
Figure S2 MEF2C binds to the MEF2 binding site M1 in the
promoter of PRL-3-iso2. EMSA was performed using MEF2-M1
wild-type and mutated probes and nuclear extracts from 293T
cells transfected with PcDNA3.1-MEF2C plasmid. Data shown
are representative of three independent experiments.
(TIF)
Figure S3 The constitutively active form of MEF2C has no
effort on the abundance of the PRL-3-iso1 transcript. Cells were
transfected with the plasmids indicated for 48 h and the
abundance of the PRL-3-iso1 transcript was evaluated by real-
time PCR. The expression data reflect mean 6 SD from three
independent experiments.
(TIF)
Figure S4 The constitutively active form of MEF2 has no effect
on the abundance of the PRL-3 protein. The 293T cell line was
transfected with the plasmids indicated for 48 h, and the
abundance of PRL-3 and GAPDH was estimated by Western
blots. Data shown are representative of three independent
experiments.
(TIF)
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